|Bid||56.61 x 1800|
|Ask||56.88 x 1000|
|Day's Range||55.89 - 56.97|
|52 Week Range||37.27 - 68.55|
|Beta (3Y Monthly)||2.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.50|
Attractive stocks have exceptional fundamentals. In the case of FibroGen, Inc. (NASDAQ:FGEN), there's is a company with impressive financial health as well as a excellent growth outlook. In the followingRead More...
Amarin Stock: The Outlook after the Q4 2018 ResultsShare price movements On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of
—Roxadustat Approved in China for Anemia in Dialysis-Dependent CKD Patients— —Primary Efficacy Endpoints Met in Seven Phase 3 Roxadustat Studies for U.S./EU—.
FibroGen Inc NASDAQ/NGS:FGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding FGEN totaled $2.42 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Tom Neff became the CEO of FibroGen, Read More...
NEW YORK, NY / ACCESSWIRE / January 17, 2019 / Despite concerns of a partial government shutdown, U.S. markets extended gains for the second consecutive session on Wednesday on strong earnings from Bank ...
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Fibrogen stock popped Thursday on results of clinical studies showing that its AstraZeneca-partnered anemia treatment in kidney disease patients could rival Amgen's.
China has for the first time approved a treatment from a global drugmaker before any other country, illustrating its recent push to bring in cutting-edge medicines—as well as Western companies’ growing interest in the market. China approved 30 innovative drugs from foreign developers in the first nine months of this year—some taking just weeks—and, according to consulting firm McKinsey & Co., is on track to at least match last year’s 40 approvals, which marked the most by the regulator in any single year for at least a decade. In 2016, China approved three such foreign drugs.
Shares of AstraZeneca Plc were up 2.8% in premarket trade Thursday after the company announced its inhaler Bevespi Aerosphere was approved by the European Commission as a treatment for symptoms of chronic obstructive pulmonary disease (COPD). The inhaler is already available to COPD patients in the U.S. Earlier on Thursday, the company announced that two major Phase 3 trials of roxadustat, a potential treatment for anemic patients with chronic kidney disease being developed with FibroGen, Inc. , had met their primary endpoints. Shares of AstroZeneca have gained 18% in the year to date, while the S&P 500 has fallen 6%.
FibroGen, Inc. (FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in the three global pivotal Phase 3 trials conducted by FibroGen: ANDES in non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients, HIMALAYAS in incident (newly initiated) dialysis patients, and SIERRAS in dialysis-dependent (DD) CKD patients. “Anemia in CKD is a serious condition for which a significant number of patients are left without treatment options in many markets,” said Thomas B. Neff, Chief Executive Officer, FibroGen.
NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...
Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]
After 25 years, FibroGen won its first drug approval, a treatment for anemia in chronic kidney disease patients in China. It hopes to follow that up with approvals in the United States, Japan and Europe over the next year.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / U.S. equities extended losses on Monday as investors await details from the Federal Reserve's final policy meeting of 2018 on Wednesday. The Dow Jones Industrial ...
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.